FDLI's Introduction to Drug Law and Regulation: The Abbreviated NDA (ANDA), 505(b)(2) Applications, and Patent and Exclusivity Issues

Food and Drug Law Institute's Introduction to Drug Law and Regulation will explore the essentials of drug law and regulation and give a comprehensive understanding of the administrative agencies that impact this industry. The event will also address patent and exclusivity issues, Rx to OTC switches, Good Manufacturing Practices (GMP), advertising and promotion, compliance, enforcement, and related issues.

Alexandra Valenti will speak on the panel, "The Abbreviated NDA (ANDA), 505(b)(2) Applications, and Patent and Exclusivity Issues" at FDLI's Introduction to Drug Law and Regulation.